First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 1

Conditions: Idiopathic Pulmonary Fibrosis

Treatments: Drug: Placebo Nebuliser solution; Drug: GSK3008348 Nebuliser solution; Radiation: GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion

Study type: Interventional

Funder types: Industry

Identifiers

NCT02612051

200262

Details and patient eligibility

About

GSK3008348 is an investigational drug, being developed by GlaxoSmithKline Research and Development Limited (the Sponsor, a pharmaceutical company based in the UK) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is a rare and poorly understood disease that causes scarring of the lungs. The main symptoms are shortness of breath and a dry cough. Symptoms generally worsen over time and in some subjects may prove fatal. The cause of IPF is unknown.

This is a First Time in Human, Phase 1, 3-part study which is being carried out on behalf of the Sponsor by Quintiles. The primary purpose of Part A is to examine the safety and tolerability of single nebulised (a medicated spray) doses of GSK3008348 following inhalation in healthy volunteers. The secondary objective is to determine how and at what rate the body absorbs, distributes, breaksdown and eliminates the drug.

Parts B and C of this study will be in-patients with Idiopathic Pulmonary Fibrosis (IPF). The purpose of Part B and C is to examine the safety and tolerability, and how much of the drug binds to its target, following single nebulised (a medicated spray) doses of GSK3008348 following inhalation in patients with Idiopathic Pulmonary Fibrosis (IPF). The secondary objective is to determine how and at what rate the bodies of these patients absorbs, distributes, breaksdown and eliminates the drug.

The total duration of Part A will be 65 - 87 days, Part B 62 days and Part C 43 days.

Enrollment: 40 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Part A:

• Male and female subjects >= 18 years at the time of signing the consent form.

Parts B and C :

• Male subjects >= 45 years and female subjects >= 55 years at the time of signing the consent form.

Part A:

• Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests, 12-lead ECG and pulmonary function tests.
• A subject with a potentially clinically significant abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator in consultation with the Medical Monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. Subjects with FEV1, FVC and DLCO values outside the normal range may be included only if the investigator in consultation with the Medical Monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.

Parts B and C:

• Subject is ambulant and capable of attending a PET scan visit as an outpatient.
• Subjects will have a diagnosis of IPF as determined by a responsible and experienced chest physician and based on established criteria defined by the American Thoracic Society/European Respiratory Society Internationale Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pnuemonias.
• FVC > 50 % predicted and DLCO > 50% predicted. Following a review of the safety data at the interim, these criteria may be altered to FVC > 50% predicted and DLCO > 40% predicted.

Part A:

• Body weight >=50 Kilogram (kg) and BMI within the range 19.0 - 35.0 kg/meter square (m^2) (inclusive).

Parts B and C:

• Body weight >=45 kg and BMI within the range 18.0 - 35.0 kg/m^2 (inclusive)
• Female subjects are eligible to participate if they are of non-childbearing potential defined as premenopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 month of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli-international unit (MIU)/millilitre (ml) and estradiol > 141 picomole (pmol)/litre (l) is confirmatory (as a precaution a pregnancy test is conducted prior to dosing, a positive test leads to exclusion).
• Male subjects with female partners of child bearing potential must comply with the following contraception requirements from the time of first dose of study medication until 90 days after the last dose of study medication. a. Vasectomy with documentation of azoospermia b. Male condom plus partner use of one of the contraceptive options below: i. Contraceptive subdermal implant that meets the Standard Operating Procedure (SOP) effectiveness criteria including a <1% rate of failure per year, as stated in the product label ii. Intrauterine device or intrauterine system that meets the SOP effectiveness criteria including a <1% rate of failure per year, as stated in the product label iii. Oral Contraceptive, either combined or progestogen alone iv. Injectable progestogen v. Contraceptive vaginal ring vi. Percutaneous contraceptive patches This is an all-inclusive list of those methods that meet the following GlaxoSmithKline (GSK) definition of highly effective: having a failure rate of less than 1% per year when used consistently and correctly and, when applicable, in accordance with the product label. For non-product methods (e.g., male sterility), the investigator determines what is consistent and correct use. The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.
• Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the consent form and in protocol

Exclusion criteria

• Alanine transaminase and bilirubin >1.5x5xupper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
• Current or history of photosensitivity.
• Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
• QT interval corrected for heart rate (QTc )> 450 millisecond (msec) or QTc > 480 msec in subjects with Bundle Branch Block
• Current upper or lower respiratory tract infection on admission to the clinical unit.

Parts B and C:

• History or suffers from claustrophobia or subject feels unable to lie flat and still on their back for a period of up to 2 hours in the PET/ CT scanner (note, one rest period will be allowed during the scan if required).
• Previous inclusion in a research and/or medical protocol involving nuclear medicine, PET or radiological investigations or occupational exposure resulting in radiation exposure greater than 10 millisievert (mSv) over the past 3 years or greater than 10 mSv in a single year including the proposed study. Clinical exposure from which the subject receives a direct benefit is not included in these calculations.
• Subjects with current IPF exacerbation, upper or lower respiratory tract infection.
• Subjects with severe co-existent chronic obstructive pulmonary disease (COPD), for example FEV1 < 60% predicted.

All Parts:

• Use of prohibited medication
• Subjects who are currently taking Pirfenidone or Nintedanib or who have received Pirfenidone or Nintedanib within the 30 days prior to the first dosing day will be excluded from the study.
• Subjects prescribed long-term continuous home oxygen therapy (those whose use of oxygen is intermittent and for symptom relief only are not excluded)
• History of alcohol consumption regularly in excess of: An average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits.
• Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 3 months prior to screening.
• History of sensitivity to heparin or heparin-induced thrombocytopenia.
• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
• Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment. Subjects with positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C Ribonucleic acid (RNA) polymerase chain reaction (PCR) test is obtained.
• A positive pre-study drug/alcohol screen.
• A positive test for human immunodeficiency virus (HIV) antibody.
• Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 56 days.
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• Exposure to more than four new chemical entities within 12 months prior to the first dosing day.

Parts B and C:

• Previous or current exposure to animals that may harbour foot and mouth disease virus (FMDV2).
• Previous long term (>= 3 months) residence in a country where FMDV2 is endemic (such as certain areas of Africa, Asia and South America)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

40 participants in 8 patient groups

Part A, Cohort 1: GSK3008348 1-3000 mcg/Placebo

Experimental group

Description:

Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.

Treatment:

Drug: GSK3008348 Nebuliser solution

Drug: Placebo Nebuliser solution

Part A, Cohort 2: GSK3008348 1-3000 mcg/Placebo

Experimental group

Description:

Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.

Treatment:

Drug: GSK3008348 Nebuliser solution

Drug: Placebo Nebuliser solution

Part A, Cohort 3: GSK3008348 1-3000 mcg/Placebo

Experimental group

Description:

Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.

Treatment:

Drug: GSK3008348 Nebuliser solution

Drug: Placebo Nebuliser solution

Part B, Cohort 4: GSK3008348/Placebo, IPF, Period 2 PET Scan

Experimental group

Description:

IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.

Treatment:

Radiation: GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion

Drug: GSK3008348 Nebuliser solution

Drug: Placebo Nebuliser solution

Part B, Cohort 5: GSK3008348/Placebo, IPF, Period 2 PET Scan

Experimental group

Description:

IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.

Treatment:

Radiation: GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion

Drug: GSK3008348 Nebuliser solution

Drug: Placebo Nebuliser solution

Part B, Cohort 6: GSK3008348/Placebo, IPF, Period 2 PET Scan

Experimental group

Description:

IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.

Treatment:

Radiation: GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion

Drug: GSK3008348 Nebuliser solution

Drug: Placebo Nebuliser solution

Part B, Cohort 7: GSK3008348/Placebo, IPF, Period 2 PET Scan

Experimental group

Description:

IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.

Treatment:

Radiation: GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion

Drug: GSK3008348 Nebuliser solution

Drug: Placebo Nebuliser solution

Part C, Cohort 8: GSK3008348, IPF, PET Scan

Experimental group

Description:

IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per Part B) in two treatment periods. There will be washout period of 6 to 14 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in both periods.

Treatment:

Radiation: GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion

Drug: GSK3008348 Nebuliser solution